Skip to main content
Top
Published in: Diabetes Therapy 5/2018

Open Access 01-10-2018 | Original Research

RETRACTED ARTICLE: Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials

Authors: Jian-Bo Zhou, Zhi-Hui Song, Lu Bai, Xiao-Rong Zhu, Hong-Bing Li, Jin-Kui Yang

Published in: Diabetes Therapy | Issue 5/2018

Login to get access

Abstract

Introduction

To explore the accumulated evidence concerning the effect of intensive blood pressure control on the incidence and progression of diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and macular edema (ME).

Methods

A number of electronic databases were searched including PubMed, EMBASE, CINAHL, Cochrane Library, conferences and proceedings. Randomized controlled trials comparing intensive blood pressure targets with conventional blood pressure targets in patients with type 2 diabetes were included. The definition of intensive versus conventional blood pressure targets was from the pertinent original studies. Meta-analyses and trial sequential analyses of randomized trials were analyzed in STATA.

Results

Eight trials randomizing 6989 patients were assessed and reviewed in full text; 3749 vs. 3240 were in each arm (intensive vs. conventional). All trials had a low risk of bias. Intensive blood pressure control supported a 17% reduction in the incidence of DR (relative risk 0.83, 95% confidence interval 0.72–0.95). Trial sequential analyses confirmed that sufficient evidence indicated a relative risk reduction above 17% for the incidence of DR when intensive blood pressure control was targeted. Heterogeneity was absent (I2 = 0%; P = 0.56). No statistically significant effect was found for intensive blood pressure targeting on the progress of DR (relative risk 0.94, 95% confidence interval 0.81–1.08). TSA showed that insufficient evidence had been found, although the Z value line appeared to have a tendency of approaching the futility boundaries. There were also no statistically significant effects on the incidence of PDR and ME (TSA-adjusted CI 0.84–1.12).

Conclusion

Intensive blood pressure control reduced the relative risk of incidence of DR by 17%. The available data were insufficient to prove or refute a relative risk reduction for the progression of DR or incidence of PDR and ME at a magnitude of 15%.
Literature
1.
go back to reference Sabanayagam C, Yip W, Ting DS, Tan G, Wong TY. Ten emerging trends in the epidemiology of diabetic retinopathy. Ophthalmic Epidemiol. 2016;23(4):209–22.CrossRefPubMed Sabanayagam C, Yip W, Ting DS, Tan G, Wong TY. Ten emerging trends in the epidemiology of diabetic retinopathy. Ophthalmic Epidemiol. 2016;23(4):209–22.CrossRefPubMed
2.
go back to reference Malek M, Khamseh ME, Aghili R, Emami Z, Najafi L, Baradaran HR. Medical management of diabetic retinopathy: an overview. Arch Iran Med. 2012;15(10):635–40.PubMed Malek M, Khamseh ME, Aghili R, Emami Z, Najafi L, Baradaran HR. Medical management of diabetic retinopathy: an overview. Arch Iran Med. 2012;15(10):635–40.PubMed
3.
4.
go back to reference Ohashi K, Hayashi T, Watanabe Y, Hara K, Ukichi R, Asano H, Suzuki H, Yamashiro K, Tojo K, Sakamoto M, Utsunomiya K. Primary aldosteronism with type 2 diabetes mellitus requires more antihypertensive drugs for blood pressure control: a retrospective observational study. J Clin Med Res. 2018;10(1):56–62.CrossRefPubMed Ohashi K, Hayashi T, Watanabe Y, Hara K, Ukichi R, Asano H, Suzuki H, Yamashiro K, Tojo K, Sakamoto M, Utsunomiya K. Primary aldosteronism with type 2 diabetes mellitus requires more antihypertensive drugs for blood pressure control: a retrospective observational study. J Clin Med Res. 2018;10(1):56–62.CrossRefPubMed
5.
go back to reference Ke CH, Morgan S, Smolina K, Gasevic D, Qian H, Khan NA. Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. BMJ Open. 2017;7(8):e013808.CrossRefPubMedPubMedCentral Ke CH, Morgan S, Smolina K, Gasevic D, Qian H, Khan NA. Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. BMJ Open. 2017;7(8):e013808.CrossRefPubMedPubMedCentral
6.
go back to reference Sjølie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract. 2011;65(2):148–53.CrossRefPubMed Sjølie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract. 2011;65(2):148–53.CrossRefPubMed
7.
go back to reference Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016;11(8):e0161897.CrossRefPubMedPubMedCentral Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016;11(8):e0161897.CrossRefPubMedPubMedCentral
8.
go back to reference UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.CrossRefPubMedCentral UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.CrossRefPubMedCentral
9.
go back to reference Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.CrossRefPubMed Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.CrossRefPubMed
10.
go back to reference Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52:2027–36.CrossRefPubMed Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52:2027–36.CrossRefPubMed
11.
go back to reference Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes eye study. Ophthalmology. 2014;121:2443–51.CrossRefPubMed Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes eye study. Ophthalmology. 2014;121:2443–51.CrossRefPubMed
12.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef
13.
go back to reference Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–93.CrossRefPubMed Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–93.CrossRefPubMed
14.
go back to reference Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63.CrossRefPubMed Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63.CrossRefPubMed
15.
go back to reference Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–100.CrossRef Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–100.CrossRef
16.
go back to reference Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406.CrossRefPubMed Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406.CrossRefPubMed
17.
go back to reference Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control z in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.CrossRefPubMed Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control z in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.CrossRefPubMed
18.
go back to reference Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58(5):776–83.CrossRefPubMed Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58(5):776–83.CrossRefPubMed
19.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.CrossRefPubMed
20.
go back to reference Higgins JPT, Green S. Cochrane handbook for systematic reviews of intervention 5.0.0. Cochrane Collaboration, 2008 (Available from cochrane-handbook.org). Higgins JPT, Green S. Cochrane handbook for systematic reviews of intervention 5.0.0. Cochrane Collaboration, 2008 (Available from cochrane-handbook.org).
21.
23.
go back to reference Crippa A, Khudyakov P, Wang M, Orsini N, Spiegelman D. A new measure of between-studies heterogeneity in meta-analysis. Stat Med. 2016;35(21):3661–75.CrossRefPubMed Crippa A, Khudyakov P, Wang M, Orsini N, Spiegelman D. A new measure of between-studies heterogeneity in meta-analysis. Stat Med. 2016;35(21):3661–75.CrossRefPubMed
24.
go back to reference Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, GRADE Working Group. What is ‘‘quality of evidence’’ and why is it important to clinicians? BMJ. 2008;336:995–8.CrossRefPubMedPubMedCentral Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, GRADE Working Group. What is ‘‘quality of evidence’’ and why is it important to clinicians? BMJ. 2008;336:995–8.CrossRefPubMedPubMedCentral
25.
go back to reference Fraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review. Clin Exp Ophthalmol. 2017;45(1):45–53.CrossRefPubMed Fraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review. Clin Exp Ophthalmol. 2017;45(1):45–53.CrossRefPubMed
26.
go back to reference Cardoso CRL, Leite NC, Dib E, Salles GF. Predictors of development and progression of retinopathy in patients with type 2 diabetes: importance of blood pressure parameters. Sci Rep. 2017;7(1):4867.CrossRefPubMedPubMedCentral Cardoso CRL, Leite NC, Dib E, Salles GF. Predictors of development and progression of retinopathy in patients with type 2 diabetes: importance of blood pressure parameters. Sci Rep. 2017;7(1):4867.CrossRefPubMedPubMedCentral
27.
go back to reference Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589–99.PubMed Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589–99.PubMed
28.
go back to reference Do DV, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.PubMed Do DV, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.PubMed
29.
go back to reference Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74.CrossRefPubMed Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials
Authors
Jian-Bo Zhou
Zhi-Hui Song
Lu Bai
Xiao-Rong Zhu
Hong-Bing Li
Jin-Kui Yang
Publication date
01-10-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0497-y

Other articles of this Issue 5/2018

Diabetes Therapy 5/2018 Go to the issue